CEBIX Raises $14.0M

La Jolla-based Cebix, a developer of treatments for type 1 diabetic neuropathy, has raised $14.0M in a new funding round, according to a regulatory filing by the firm today. Details on the funding have not been announced by the company, however, the filing indicates that Sofinnova Venture Partners, InterWest Partners, Thomas McNerney & Partners, and Creative Peptides Sweden are all now represented on the firm's board. Sofinnova was a prior investor in the firm, as was Healthcap Venture Capital. According to the firm's web site, it is looking to file an IND by the end of the year, to allow safety testing on humans of its technology. More information »